TLR7 agonist in combination with Salmonella as an effective antimelanoma immunotherapy
Aim: We evaluated a novel approach combining the use of attenuated Salmonella immunotherapy with a Toll-like receptor agonist, imiquimod, in B16F1 melanoma-bearing mice. Materials & methods: B16F1 melanoma-bearing mice were daily treated with topical imiquimod in combination with one intratumora...
| Autores: | , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2018 |
| País: | Uruguay |
| Institución: | Universidad de la República |
| Repositorio: | COLIBRI |
| Idioma: | inglés |
| OAI Identifier: | oai:colibri.udelar.edu.uy:20.500.12008/42097 |
| Acceso en línea: | https://hdl.handle.net/20.500.12008/42097 |
| Access Level: | acceso abierto |
| Palabra clave: | Experimental model Imiquimod Immunotherapy Melanoma Salmonella |
| Sumario: | Aim: We evaluated a novel approach combining the use of attenuated Salmonella immunotherapy with a Toll-like receptor agonist, imiquimod, in B16F1 melanoma-bearing mice. Materials & methods: B16F1 melanoma-bearing mice were daily treated with topical imiquimod in combination with one intratumoral injection of attenuated Salmonella enterica serovar Typhimurium LVR01. Results: The combined therapy resulted in retarded tumor growth and prolonged survival. Combination treatment led to an enhancement in the expression of pro-inflammatory cytokines and chemokines in the tumor microenvironment, with a Th1-skewed profile, resulting in a broad antitumor response. The induced immunity was effective in controlling the occurrence of metastasis. Conclusion: Salmonella LVR01 immunotherapy in combination with imiquimod is a novel approach that could be considered as an effective antimelanoma therapy. |
|---|